Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson's DiseaseBusiness Wire • Monday
Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024Business Wire • 08/19/24
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial ResultsBusiness Wire • 08/12/24
Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer's Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in MadridBusiness Wire • 08/02/24
Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor AgonistsBusiness Wire • 07/31/24
Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the ClinicBusiness Wire • 06/20/24
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in NeurologyBusiness Wire • 06/11/24
Coya Therapeutics: Potential Milestone For The Treatment Of Alzheimer's This SummerSeeking Alpha • 06/10/24
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in NeurologyBusiness Wire • 06/03/24
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's DiseaseBusiness Wire • 05/22/24
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer's Drug Discovery Foundation (ADDF)Business Wire • 05/20/24
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial ResultsBusiness Wire • 05/09/24
Why Coya Therapeutics Is A Smart Speculative Buy For Neurodegenerative DiseasesSeeking Alpha • 05/01/24
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center SymposiumBusiness Wire • 04/26/24
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development SummitBusiness Wire • 04/18/24
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center SymposiumBusiness Wire • 04/08/24
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial ResultsBusiness Wire • 03/19/24
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology ConferenceBusiness Wire • 03/12/24
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 ConferenceBusiness Wire • 03/06/24
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 ConferenceBusiness Wire • 02/29/24